BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
176 hedge funds and large institutions have $309M invested in bluebird bio in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 70 increasing their positions, 41 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
12% less call options, than puts
Call options by funds: $3.48M | Put options by funds: $3.97M
23% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 31
32% less capital invested
Capital invested by funds: $456M → $309M (-$147M)
Holders
176
Holding in Top 10
1
Calls
$3.48M
Puts
$3.97M
Top Buyers
| 1 | +$16.7M | |
| 2 | +$15.9M | |
| 3 | +$13.8M | |
| 4 |
DM
Deerfield Management
New York
|
+$6.92M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$6.4M |
Top Sellers
| 1 | -$4.33M | |
| 2 | -$2.51M | |
| 3 | -$2.51M | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$2.3M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.6M |